Psoriasis is increasingly recognized as a systemic inflammatory condition associated with elevated risks of cardiovascular disease, metabolic syndrome, obesity, and type 2 diabetes, largely driven by chronic low-grade inflammation mediated through the IL-17/23 axis [43]. Here, IL17A is linked to metabolic syndrome.